Antiplatelet drugs reduced restenosis/reocclusion at six months after peripheral endovascular treatment, with cilostazol showing superior results at 12 months compared to ticlopidine.
Do antiplatelet and anticoagulant drugs reduce restenosis/reocclusion in patients following peripheral endovascular treatment?
There is limited, low-quality evidence suggesting antiplatelet and anticoagulant therapies may reduce restenosis after peripheral endovascular treatment, highlighting a need for large-scale, high-quality RCTs.
Absolute Event Rate: 0% vs 0%
There is limited evidence suggesting that restenosis/reocclusion at six months following peripheral endovascular treatment is reduced by use of antiplatelet drugs compared with placebo/control, but associated information on bleeding and gastrointestinal side effects is lacking. There is also some evidence of variation in effect according to different drugs with cilostazol reducing reocclusion/restenosis at 12 months compared with ticlopidine and both LMWH and batroxobin combined with aspirin appearing beneficial compared with aspirin alone. However, available trials are generally small and of variable quality and side effects of drugs are not consistently addressed. Further good quality, large-scale RCTs, stratified by severity of disease, are required.
Robertson et al. (Wed,) reported a other. Antiplatelet drugs reduced restenosis/reocclusion at six months after peripheral endovascular treatment, with cilostazol showing superior results at 12 months compared to ticlopidine.